[Strontium ranelate].
Strontium ranelate, which has dual effects of decreasing bone resorption and increasing bone formation, is a new orally active drug to treat osteoporosis. Although the clinical values are scientifically proved and the governments admit as one of the treatment for osteoporosis in many countries, the clinical trial is still undergoing in Japan.
Masaki
Hideki
H
Geriatric Medicine, Postgraduate School of Medicine, Osaka City University Medical School.
Miki
Takami
T
D000368:Aged; D000369:Aged, 80 and over; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000494:pharmacology; D001862:Bone Resorption / Q000517:prevention & control; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008875:Middle Aged; D009942:Organometallic Compounds / Q000008:administration & dosage* / Q000494:pharmacology; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D013876:Thiophenes / Q000008:administration & dosage* / Q000494:pharmacology
D050071:Bone Density Conservation Agents; D009942:Organometallic Compounds; D013876:Thiophenes; C081587:strontium ranelate